Goldman Sachs Discloses Passive Stake in BioLife Solutions
Ticker: BLFS · Form: SC 13G · Filed: Feb 2, 2024 · CIK: 834365
| Field | Detail |
|---|---|
| Company | Biolife Solutions Inc (BLFS) |
| Form Type | SC 13G |
| Filed Date | Feb 2, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, SC-13G
TL;DR
**Goldman Sachs just revealed a stake in BioLife Solutions, signaling institutional interest.**
AI Summary
Goldman Sachs Group Inc. filed an SC 13G on February 2, 2024, disclosing its ownership of BioLife Solutions Inc. common stock as of December 29, 2023. This filing indicates that Goldman Sachs holds a significant, though passive, stake in BioLife Solutions, a company specializing in electromedical and electrotherapeutic apparatus. This matters to investors because a major financial institution like Goldman Sachs taking a position can signal confidence in the company's future prospects, potentially influencing other investors and the stock price.
Why It Matters
This filing shows a major institutional investor, Goldman Sachs, has a position in BioLife Solutions, which can be seen as a vote of confidence in the company's value.
Risk Assessment
Risk Level: low — This is a passive filing by an institutional investor, indicating a standard investment rather than an activist position or a significant change in company control.
Analyst Insight
Investors might consider this a positive signal, suggesting that a major institution sees value in BioLife Solutions. It warrants further research into BioLife Solutions' fundamentals and recent performance.
Key Players & Entities
- Goldman Sachs Group Inc. (company) — filer of the SC 13G
- BIOLIFE SOLUTIONS INC (company) — subject company of the filing
- December 29, 2023 (date) — date of event requiring the filing
- February 2, 2024 (date) — date the filing was made
- $0.001 (dollar_amount) — par value per share of common stock
FAQ
What type of filing is this and what does it generally indicate?
This is an SC 13G filing, which is typically used by institutional investors who acquire more than 5% of a company's stock but do not intend to influence or control the company's management or policies. It indicates a passive investment.
Who is the filer of this SC 13G statement?
The filer of this SC 13G statement is Goldman Sachs Group Inc., with a Central Index Key (CIK) of 0000886982.
What is the subject company of this filing?
The subject company is BIOLIFE SOLUTIONS INC, identified by CIK 0000834365, which operates in the electromedical & electrotherapeutic apparatus industry.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 29, 2023, as stated in the filing.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the 'X' in the appropriate box on the cover page.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on February 2, 2024 regarding BIOLIFE SOLUTIONS INC (BLFS).